MRNA - Moderna Inc.

Cited as an example of AI/biotech breakthroughs — a phase 3 trial producing a ~48% survival rate that sent the stock up ~150% on the news.

Already ran up 122% in one day; he says he won't go back there, implying he is staying away at current levels.

Positive momentum after cancer vaccine news; if it breaks out above 154.70, watch for more upside price action.

Host continues watching MRNA to the downside; expects a move down if it breaks below the triple bottom near $137.65.

Host is watching for a breakdown below $145 to short the stock due to recent volatility.

Would be selling after 176% one-day move; no insider buying; unless it truly cured cancer, he hits the sell button at $135.

Discussed as an example of a biotech catalyst (cancer cure collaboration) that drove a 160% one-day surge, but the host advises against chasing the monster move and instead suggests looking for companies with strong fundamentals not yet run up.

Stock down 25% after being up 3x on phase three cancer vaccine news. Described as a battleground stock with unknowns, hype, and heavy short interest; direction unclear.

Reported 180% surge on positive Phase 3 cancer vaccine data; host highlighted record gain and big money trade but did not give explicit personal recommendation.

Moderna spiked on positive phase 3 cancer vaccine data, but hosts said they would not buy at current levels due to hype and uncertainty. They also mentioned they would not short a potential cure, keeping a neutral stance.